Speaker Profile
COO, Eximius Diagnostics
Biography
Matthew Smalley is a life sciences professional with 10 years of experience in the operations and program management of cancer diagnostics startups. He has led work across the full development pipeline—from assay design to regulatory and clinical trial strategy—supporting liquid biopsy technologies built on circulating tumor cells and extracellular vesicles (EVs). As COO of Eximius, he currently oversees Eximius' Phase 2 SBIR-funded EV-based liquid biopsy assay for hepatocellular carcinoma, coordinating between research, clinical, and industry teams. Matthew collaborates closely with UCLA's Liquid Biopsy Laboratory and helps organize SoCalBio's Innovation Catalyst Program.
Talk
An EV Liquid Biopsy Platform for HCC and Beyond
Extracellular vesicles are an abundant liquid biopsy analyte that reflect the molecular profile of their parental tumor cells, enabling non-invasive disease assessment via affordable techniques like qPCR. Eximius' EV platform powers its FDA Breakthrough Device-Designated HCC blood test, as well as assays designed for diagnosis, MRD detection, and treatment response monitoring in other cancers.
Clinical Dx Showcase:
Eximius Diagnostics Corp
Eximius Diagnostics is a UCLA spinoff developing extracellular vesicle (EV)-based liquid biopsy tests for cancer detection and monitoring. Through a Phase-II SBIR, the NCI has supported the development of Eximius' lead product, an FDA Breakthrough Device-Designated blood test for hepatocellular carcinoma designed to replace ultrasound as the standard screening tool for at-risk liver patients.
Session Abstract – PMWC 2027 Silicon Valley
The PMWC 2027 Data Applications in Clinical Diagnostics Showcase will provide a 15-30 minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.
- Clinical Dx/Oncology (including Liquid Biopsy)
- Clinical Dx/Cardio Vascular
- Clinical Dx/Neurodegenerative
Davos of Precision Medicine
PMWC 2027 Program
January 27–29, 2027 · Santa Clara Convention Center
Swipe speakers · Tap a card for sessions →
In a few words.
PMWC is indeed The Davos of Biotech
PMWC Hall of Impact
Previous Speakers Include
Nobel laureates, technology founders, regulators, CEOs and scientific pioneers who have taken the PMWC stage.
